Suppr超能文献

在存在CPI-613和羟氯喹的情况下,通过ERp57/PDIA3抗体诱导黑色素瘤细胞凋亡。

Inducing Melanoma Cell Apoptosis by ERp57/PDIA3 Antibody in the Presence of CPI-613 and Hydroxychloroquine.

作者信息

Ichiki Naohisa, Saigo Chiemi, Hanamatsu Yuki, Iwata Hiroaki, Takeuchi Tamotsu

机构信息

Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan.

Department of Pathology and Translational Research, Gifu University Graduate School of Medicine, Gifu, Japan.

出版信息

J Cancer. 2024 Feb 4;15(7):1779-1785. doi: 10.7150/jca.92252. eCollection 2024.

Abstract

The combination of the cancer mitochondrial metabolic inhibitor CPI-613 and hydroxychloroquine has tumor-suppressive effects on clear cell sarcoma, which shares pathobiological properties with melanoma. Therefore, we intended to examine the effects of a combination of CPI-613 and hydroxychloroquine on the growth of melanoma cells in the present study. However, cell death was not induced in melanoma cells. Therefore, a monoclonal antibody, ICT, that induced apoptosis in melanoma cells in combination with CPI-613 and hydroxychloroquine was developed. Immunoprecipitation, mass spectrometry, and small interfering RNA (siRNA)-mediated gene silencing demonstrated that ICT targeted Endoplasmic Reticulum Resident Protein 57/ Protein Disulfide Isomerase Family A Member 3 (ERp57/PDIA3), which was first identified as being upregulated by metabolic depletion stress and is localized on the cell surface during immunogenic cell death. The combination of CPI-613 and hydroxychloroquine enhanced the localization of ERp57/PDIA3 to the surface of melanoma cells. siRNA-mediated downregulation of ERp57/PDIA3 did not significantly induce ICT-mediated apoptosis in melanoma cells in the presence of CPI-613 and hydroxychloroquine. Therefore, the ICT antibody acts as a tumor suppressor in melanoma cells by targeting the cell membrane ERp57/PDIA3, expression of which was enhanced by the combination of CPI-613 and hydroxychloroquine.

摘要

癌症线粒体代谢抑制剂CPI-613与羟氯喹啉联合使用对透明细胞肉瘤具有肿瘤抑制作用,透明细胞肉瘤与黑色素瘤具有共同的病理生物学特性。因此,在本研究中我们打算检测CPI-613与羟氯喹啉联合使用对黑色素瘤细胞生长的影响。然而,黑色素瘤细胞未发生细胞死亡。因此,开发了一种单克隆抗体ICT,其与CPI-613和羟氯喹啉联合使用可诱导黑色素瘤细胞凋亡。免疫沉淀、质谱分析和小干扰RNA(siRNA)介导的基因沉默表明,ICT靶向内质网驻留蛋白57/蛋白二硫键异构酶家族A成员3(ERp57/PDIA3),该蛋白最初被鉴定为在代谢耗竭应激下上调,并在免疫原性细胞死亡期间定位于细胞表面。CPI-613与羟氯喹啉联合使用增强了ERp57/PDIA3在黑色素瘤细胞表面的定位。在存在CPI-613和羟氯喹啉的情况下,siRNA介导的ERp57/PDIA3下调并未显著诱导ICT介导的黑色素瘤细胞凋亡。因此,ICT抗体通过靶向细胞膜上的ERp57/PDIA3在黑色素瘤细胞中发挥肿瘤抑制作用,CPI-613与羟氯喹啉联合使用可增强该蛋白的表达。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c442/10905412/125bec2622ac/jcav15p1779g001.jpg

相似文献

1
Inducing Melanoma Cell Apoptosis by ERp57/PDIA3 Antibody in the Presence of CPI-613 and Hydroxychloroquine.
J Cancer. 2024 Feb 4;15(7):1779-1785. doi: 10.7150/jca.92252. eCollection 2024.
2
ERp57/PDIA3 binds specific DNA fragments in a melanoma cell line.
Gene. 2013 Jul 25;524(2):390-5. doi: 10.1016/j.gene.2013.04.004. Epub 2013 Apr 13.
3
AP3B1 facilitates PDIA3/ERP57 function to regulate rabies virus glycoprotein selective degradation and viral entry.
Autophagy. 2024 Dec;20(12):2785-2803. doi: 10.1080/15548627.2024.2390814. Epub 2024 Aug 17.
4
ERp57 is protective against mutant SOD1-induced cellular pathology in amyotrophic lateral sclerosis.
Hum Mol Genet. 2018 Apr 15;27(8):1311-1331. doi: 10.1093/hmg/ddy041.
5
ERp57/PDIA3: new insight.
Cell Mol Biol Lett. 2022 Feb 2;27(1):12. doi: 10.1186/s11658-022-00315-x.
6
Insights into the role of ERp57 in cancer.
J Cancer. 2021 Mar 1;12(8):2456-2464. doi: 10.7150/jca.48707. eCollection 2021.
7
PDIA3 Expression in Glioblastoma Modulates Macrophage/Microglia Pro-Tumor Activation.
Int J Mol Sci. 2020 Nov 3;21(21):8214. doi: 10.3390/ijms21218214.
8
Endoplasmic reticulum-resident protein 57 (ERp57) oxidatively inactivates human transglutaminase 2.
J Biol Chem. 2018 Feb 23;293(8):2640-2649. doi: 10.1074/jbc.RA117.001382. Epub 2018 Jan 5.
9
Proapoptotic activities of protein disulfide isomerase (PDI) and PDIA3 protein, a role of the Bcl-2 protein Bak.
J Biol Chem. 2015 Apr 3;290(14):8949-63. doi: 10.1074/jbc.M114.619353. Epub 2015 Feb 19.

本文引用的文献

1
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.
NEJM Evid. 2023 Apr;2(4):EVIDoa2200239. doi: 10.1056/EVIDoa2200239. Epub 2023 Mar 22.
2
Protein disulfide isomerase family mediated redox regulation in cancer.
Adv Cancer Res. 2023;160:83-106. doi: 10.1016/bs.acr.2023.06.001. Epub 2023 Jul 18.
4
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma.
Curr Oncol Rep. 2023 Jun;25(6):647-657. doi: 10.1007/s11912-023-01406-4. Epub 2023 Apr 1.
5
Experimental model of micronodular thymic neoplasm with lymphoid stroma.
Thorac Cancer. 2023 Feb;14(4):357-362. doi: 10.1111/1759-7714.14716. Epub 2022 Dec 16.
6
Melanoma: Molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance.
Genes Dis. 2022 Apr 27;9(6):1608-1623. doi: 10.1016/j.gendis.2022.04.004. eCollection 2022 Nov.
7
ERp57/PDIA3: new insight.
Cell Mol Biol Lett. 2022 Feb 2;27(1):12. doi: 10.1186/s11658-022-00315-x.
8
Targeting cancer metabolism in the era of precision oncology.
Nat Rev Drug Discov. 2022 Feb;21(2):141-162. doi: 10.1038/s41573-021-00339-6. Epub 2021 Dec 3.
10
Human colorectal cancer-associated carbohydrate antigen on annexin A2 protein.
J Mol Med (Berl). 2021 Aug;99(8):1115-1123. doi: 10.1007/s00109-021-02077-z. Epub 2021 Apr 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验